Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

130.41 +0.18 (+0.14%)
Streaming Delayed Price Updated: 3:05 PM EDT, May 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
66 67 Next >
After FDA Regulatory Setback, Penny Stock ObsEva Cuts 70% Of Its Staff
Via Benzinga
This Is What Whales Are Betting On Merck & Co
A whale with a lot of money to spend has taken a noticeably bearish stance on Merck & Co. Looking at options history for Merck & Co (NYSE:MRK) we detected 17 strange trades. 
Via Benzinga
Analyst Ratings for Merck & Co
Analysts have provided the following ratings for Merck & Co (NYSE:MRK) within the last quarter: 
Via Benzinga
BP To $47? Plus UBS Sees $2,260 For This Stock
  Piper Sandler boosted the price target for BP p.l.c. (NYSE: BP) from $44 to $47. BP shares rose 2.1% to trade at $32.34 on Monday. 
Via Benzinga
Five-Year Data For Merck's Keytruda Plus Chemo Shows Sustained Survival Benefit In Lung Cancer Patients
Via Benzinga
Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer
Via Benzinga
Merck Gambled With Keytruda In 2011 — How That Jump Is Still Paying Off Today
In two new studies, Keytruda doubled patients' survival rate after five years. 
Via Investor's Business Daily
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
Via Benzinga
AstraZeneca-Merck's Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer
Via Benzinga
Top Financial Stories Thursday, September 1: Netflix Weighs Charging High Sum For Ads, Self Harm posts Grow On Twitter, California Fast-Food Bill Faces Industry Backlash...
Wall Street Journal 
Via Benzinga
Novartis Appoints Merck Executive As Research Head
Via Benzinga
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
Via Benzinga
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
These names are benefitting from M&A, clinical data and promising regulatory actions. 
Via Investor's Business Daily
Bristol Myers-JNJ Partnered Secondary Stroke Drug Misses Endpoint, But Companies See Enough Potential For Phase 3 Trials
Via Benzinga
Merck's Rumored $40 Billion Seagen Takeover Hits A Snag On Price
The companies could still reach a deal, but have failed to see eye to eye on price. 
Via Investor's Business Daily
Benzinga Before The Bell: Elon Musk's Demand For Broad Twitter Data Dismissed, Xiaomi Wants To Join EV Race, Bed Bath & Beyond Plans To Share Turnaround Strategy Next Week And Other Top Financial Stories Friday, August 26
CNBC The Aviation Sector Is Slammed By Sky-High Rents 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting off the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
Merck's Buyout Of Seagen Hits Speed Braker Over Price Agreement: Report
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Back-To-Back Three Japanese Approvals For AstraZeneca's Rare Disease Treatments
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Merck Gets FDA Fast Track Status For Chronic Kidney Disease Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck's (NYSE: MRK) lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients... 
Via Benzinga
Gilead's Lenacapavir Scores European Approval For Pretreated HIV Patients After Manufacturing Delays
Via Benzinga
Benzinga Before The Bell: Apple Employees Resist Calls For Return-To-Office, Tesla About To Hike FSD Prices Again, MGM China Injects $594M Into Macau Unit And Other Top Financial Stories Monday, August 22
Reuters Vodafone To Sell Hungarian Business For $1.8B: Report 
Via Benzinga
FDA Says Study Needed To Assess Another Round Of Pfizer's COVID-19 Pill As Infection Rebounds
The FDA has asked Pfizer Inc (NYSE: PFE) to test an additional course of its antiviral Paxlovid among people who experience a rebound in COVID-19 after treatment. 
Via Benzinga
Looking For Ebola Virus Meds? WHO Recommends These Two Antibody Treatments
Via Benzinga
Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions
How they handle an upcoming shift in payments will be telling for their tailwind. 
Via Investor's Business Daily
Could This Company's HyBryte™ Provide A Safer, More Convenient Alternative To Cutaneous T-Cell Lymphoma Treatment?
Patients always have hope if their cancers are detected early. Thanks to advanced research and therapies, the earlier the cancer is diagnosed and treated, the better the chance of it being cured. 
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
3 Top Stocks to Invest In Right Now
Every investor is looking for the top stocks to invest in. These three options will provide you with both offense and defense. 
Via InvestorPlace
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
66 67 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.